An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome-Reference-Cited by-同舟云学术

An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome

Published:2023-04 Issue: Volume:79 Page:102201
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Begg Malcolm^ORCID,Amour Augustin,Jarvis Emily,Tang Teresa,Franco Sara Santos,Want Andrew,Beerahee Misba,Fernando Disala,Karkera Yakshitha,Sander Clare,Southworth Thomas,Singh Dave,Clark Jonathan,Nejentsev Sergey,Okkenhaug Klaus,Condliffe Alison,Chandra Anita,Cahn Anthony,Hall Edward Banham

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry (medical),Pulmonary and Respiratory Medicine

Reference34 articles.

1. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase δ syndrome registry;Maccari;Front. Immunol.,2018

2. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage;Angulo;Science,2013

3. PI3Kδ and primary immunodeficiencies;Lucas;Nat. Rev. Immunol.,2016

4. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome;Condliffe;Front. Immunol.,2018

5. Infections in activated PI3K delta syndrome (APDS);Brodsky;Curr. Opin. Immunol.,2021

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment;Pediatric Discovery;2024-08-23

2. Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders;Global and Regional Health Technology Assessment;2024-05-22

3. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment;Italian Journal of Pediatrics;2024-05-20

4. Interim analysis: Open-label extension study of leniolisib for patients with APDS;Journal of Allergy and Clinical Immunology;2024-01

5. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond;The Journal of Allergy and Clinical Immunology: In Practice;2024-01